{"id":83108,"date":"2023-01-16T21:31:16","date_gmt":"2023-01-16T18:01:16","guid":{"rendered":"https:\/\/aprinpharmed.com\/hynic-bombesine\/"},"modified":"2023-01-24T18:34:28","modified_gmt":"2023-01-24T15:04:28","slug":"hynic-bombesine","status":"publish","type":"page","link":"https:\/\/aprinpharmed.com\/en\/hynic-bombesine\/","title":{"rendered":"HYNIC BOMBESINE"},"content":{"rendered":"

[vc_row][vc_column]

Aprin Pharmed<\/div>
_<\/span>

HYNIC BOMBESINE<\/h1>\n

 <\/p>\n

 <\/p>\n

Bombesin is a 14-amino acid peptide with diverse biological activity and also has a high affinity for GRP receptors. GRP receptors are highly expressed in various malignant tumors such as prostate and breast. 2-hydrazinonicotinamide (HYNIC) is a dual-purpose chelating ligand that has attracted the attention of many researchers in the design and development of technetium and rhenium-based radiopharmaceuticals in recent years.
\nHynic Bombesine is readily labeled with 99mTc and used as a potential imaging agent for GRP receptor-positive tumors.<\/p>\n

\"\"<\/p>\n<\/div>_<\/span><\/div><\/div>[\/vc_column][\/vc_row][vc_row][vc_column width=”1\/6″][\/vc_column][vc_column width=”2\/3″]

CAS registration number<\/div><\/span>
  • <\/i><\/div>
    -<\/span><\/div><\/li><\/ul><\/div><\/div>
    Molecular weight<\/div><\/span>
    • <\/i><\/div>
      1160.35 g\/mol<\/span><\/div><\/li><\/ul><\/div><\/div>
      molecular formula<\/div><\/span>
      • <\/i><\/div>
        C53H77N17O11S<\/span><\/div><\/li><\/ul><\/div><\/div>
        Appearance<\/div><\/span>
        • <\/i><\/div>
          Solid powder<\/span><\/div><\/li><\/ul><\/div><\/div>
          Maintenance<\/div><\/span>
          • <\/i><\/div>
            Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).<\/span><\/div><\/li><\/ul><\/div><\/div>
            Therapeutic applications<\/div><\/span>
            • <\/i><\/div>
              Positron Emission Tomography (PET) imaging or radionuclide therapy<\/span><\/div><\/li><\/ul><\/div><\/div><\/div><\/div>[\/vc_column][vc_column width=”1\/6″][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"

              [vc_row][vc_column][\/vc_column][\/vc_row][vc_row][vc_column width=”1\/6″][\/vc_column][vc_column width=”2\/3″][\/vc_column][vc_column width=”1\/6″][\/vc_column][\/vc_row] … <\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-83108","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/83108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/comments?post=83108"}],"version-history":[{"count":7,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/83108\/revisions"}],"predecessor-version":[{"id":83230,"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/pages\/83108\/revisions\/83230"}],"wp:attachment":[{"href":"https:\/\/aprinpharmed.com\/en\/wp-json\/wp\/v2\/media?parent=83108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}